The rising interest in psychedelics, particularly for treating anxiety disorders, stems from studies highlighting psilocybin's potential in alleviating illness-related anxiety. Recent clinical trials, including a phase II trial in 2023, have shown that administering LSD alongside psychotherapy can effectively reduce anxiety symptoms for an extended period of up to 16 weeks. However, the underlying neural mechanisms of these psychedelics are not fully understood. Research by Muir and colleagues is beginning to shed light on the brain circuits involved in these therapeutic effects, offering hope for innovative treatment pathways for anxiety disorders.
Psychedelics are becoming a promising therapeutic option for anxiety, with studies showing psilocybin relieving illness-related anxiety and LSD reducing symptoms for up to 16 weeks.
Understanding the neural circuits that mediate psychedelic benefits could lead to new anxiety treatments, addressing a serious and often undertreated condition.
Collection
[
|
...
]